The Arthur and Linda Gelb Center for Translational Research provides a platform and support for investigators at Dana-Farber, collaborating institutions, and industry — to promote discoveries in the biology of genitourinary (GU) cancers, and to translate
these findings into clinical benefit. The Gelb Center fosters collaboration across traditional boundaries by providing access to a wide array of high-quality and well-characterized human biospecimens and clinical data for the advancement of clinical
and translational research.
The Gelb Center for Translational Research was founded by Arthur and Linda Gelb in 2000 to foster translational research in prostate cancer. In March of 2001, the Gelb Center began to consent patients for tissue, blood, clinical data, and future re-contact.
Today, the Gelb Center maintains blood and tissue specimen repositories and a large clinical database. We provide these resources to help investigators make or confirm discoveries relevant to GU cancer research. To date, thousands of patients with prostate,
kidney, and bladder cancer have contributed to specimen banking and clinical databases. The Gelb Center has an extensive history of providing resources to investigator-initiated and industry-initiated research projects that have resulted in publications
in top scientific journals.
The highest ethical standards
The Gelb Center obtains and distributes de-identified clinical data and/or biospecimens with adherence to strict quality and ethical standards. The Gelb Center recognizes the ethical standards and ensures that samples are collected under the necessary
guidelines set forth by the Dana-Farber IRB and ethics committees, and follows HIPAA guidelines and Good Clinical Practices.